Affinage

PAPSS2

Bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthase 2 · UniProt O95340

Length
614 aa
Mass
69.5 kDa
Annotated
2026-06-10
27 papers in source corpus 14 papers cited in narrative 14 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

PAPSS2 is a bifunctional PAPS synthetase that produces 3'-phosphoadenosine 5'-phosphosulfate, the universal sulfate donor consumed by sulfotransferases, and its enzymatic output underlies both steroid metabolism and skeletal extracellular matrix sulfation (PMID:19474428, PMID:10679223). In the adrenal/steroidogenic axis, PAPSS2-generated PAPS is required for SULT2A1-catalyzed sulfation of DHEA to DHEAS; compound heterozygous inactivating mutations abolish this activity in vitro, and in vivo loss of DHEA sulfation increases 5α-reductase activity and active androgen production, defining a Mendelian androgen-excess phenotype (PMID:19474428, PMID:25594860). The same enzymatic loss disrupts cartilage proteoglycan sulfation, and loss-of-function PAPSS2 mutations cause autosomal recessive brachyolmia, while mouse loss of activity produces degenerative joint disease, establishing PAPSS2 as essential for articular cartilage homeostasis (PMID:23824674, PMID:15882565). Disease-associated mutations impair function either by destabilizing the structurally fragile APS kinase domain or by directly reducing catalysis and substrate affinity (PMID:11773860, PMID:35463959). In chondrocytes PAPSS2 expression is driven by TGF-β acting through SOX9, which post-translationally stabilizes and binds the repressor C/EBPβ to derepress a Sox9-responsive element in the Papss2 promoter (PMID:22394585, PMID:27746378, PMID:40453446). Beyond skeletal and steroid biology, Snail-induced PAPSS2 drives sulfation of versican to promote breast cancer cell migration and metastasis (PMID:29955124).

Mechanistic history

Synthesis pass · year-by-year structured walk · 14 steps
  1. 2000 Medium

    Established PAPSS2 as a discrete human PAPS synthetase gene with defined structure and chromosomal location, providing the molecular foundation for all subsequent functional work.

    Evidence Gene cloning, Northern blot, and FISH mapping to 10q22-23

    PMID:10679223

    Open questions at the time
    • Does not address catalytic mechanism or physiological substrates
    • No tissue-specific expression regulation defined
  2. 2002 High

    Resolved that natural variant allozymes impair PAPS synthase activity through distinct molecular routes—reduced protein versus reduced substrate affinity—linking genotype to specific catalytic defects.

    Evidence Transient expression, PAPSS activity and kinetic (Km for ATP, Na2SO4) assays of variant allozymes

    PMID:11773860

    Open questions at the time
    • Allozyme effects not connected to a clinical phenotype here
    • No structural basis for affinity loss defined
  3. 2005 Medium

    Demonstrated that PAPSS2 enzymatic activity is required in vivo for articular cartilage homeostasis, moving the gene from biochemical entity to a determinant of joint integrity.

    Evidence Histology and micro-CT of brachymorphic Papss2 mutant mice

    PMID:15882565

    Open questions at the time
    • Does not identify which proteoglycan sulfation events are deficient
    • Single lab; molecular mechanism of degeneration not dissected
  4. 2009 High

    Defined the steroidogenic role by showing PAPSS2 supplies the PAPS donor for SULT2A1-mediated DHEA sulfation, explaining how its loss causes androgen excess.

    Evidence In vitro co-incubation of SULT2A1 with WT/mutant PAPSS2; patient with compound heterozygous mutations

    PMID:19474428

    Open questions at the time
    • In vitro reconstitution; downstream androgen consequences not quantified in this study
    • Other sulfotransferase dependencies not tested
  5. 2012 Medium

    Confirmed that PAPSS2 missense variants in brachyolmia are loss-of-function, establishing enzyme inactivation as the cause of this autosomal recessive skeletal dysplasia.

    Evidence In vitro enzyme assays of missense mutant proteins

    PMID:23824674

    Open questions at the time
    • Single study
    • Does not link specific cartilage sulfation defect to skeletal phenotype
  6. 2012 High

    Placed PAPSS2 downstream of TGF-β in cartilage, showing its expression controls the balance of sulfated versus unsulfated chondroitin and cartilage biomechanics.

    Evidence Microarray, RT-PCR, dominant-negative TGF-β receptor mice, chondroitin sulfate immunofluorescence, mechanical indentation

    PMID:22394585

    Open questions at the time
    • Transcription factor mediating TGF-β induction not yet identified at this stage
    • Direct promoter regulation not shown
  7. 2012 Medium

    Extended PAPSS2 function to osteoblast biology, linking it to alkaline phosphatase activity, mineralization, and phospho-Smad signaling.

    Evidence RNAi knockdown/overexpression in MC3T3-E1 osteoblasts, ALP/mineralization assays, phospho-Smad2/3 Western blot

    PMID:22916269

    Open questions at the time
    • Smad linkage is correlative
    • Sulfation substrate mediating osteoblast effect not identified
  8. 2015 High

    Provided in vivo metabolic confirmation that PAPSS2 mutations impair DHEA sulfation and drive active androgen production, with allele-specific severity.

    Evidence DHEA challenge test with mass spectrometry metabolite profiling plus in vitro mutant characterization

    PMID:25594860

    Open questions at the time
    • Mechanism linking reduced DHEAS to increased 5α-reductase flux not fully resolved
    • Tissue-specific contributions not separated
  9. 2016 Medium

    Identified SOX9 as the necessary and sufficient transcriptional mediator of TGF-β-induced PAPSS2 expression, via post-translational SOX9 stabilization.

    Evidence Adenoviral SOX9 overexpression, Sox9/Smad3 siRNA, qPCR and Western blot in chondrocytes and ATDC5 cells

    PMID:27746378

    Open questions at the time
    • Did not define the cis-element or how SOX9 acts on the promoter
    • Single lab
  10. 2018 High

    Revealed a pro-metastatic role: Snail-induced PAPSS2 sulfates versican to drive breast cancer migration and lung metastasis.

    Evidence shRNA/overexpression, sodium chlorate inhibition, Transwell assays, nude mouse lung metastasis, VCAN depletion

    PMID:29955124

    Open questions at the time
    • Direct sulfation of VCAN by PAPSS2-dependent sulfotransferases not biochemically mapped
    • Generalization beyond breast cancer not tested here
  11. 2018 Low

    Connected PAPSS2 to chondrocyte differentiation programs, correlating its level with chondrogenic markers and Wnt pathway components.

    Evidence Knockdown/overexpression in ATDC5 cells, RT-PCR and protein analysis

    PMID:30546414

    Open questions at the time
    • Wnt/β-catenin pathway placement is correlative and not rigorously tested
    • Single lab; indirect mRNA evidence
  12. 2022 Medium

    Showed that the APS kinase domain is intrinsically fragile, with disease mutations causing either aggregation/destabilization or catalytic deactivation, explaining diverse mutational mechanisms.

    Evidence Cellular stability and aggregation assays of clinical APS kinase domain mutants

    PMID:35463959

    Open questions at the time
    • No high-resolution structure presented
    • Single lab; methods not fully detailed
  13. 2024 Medium

    Implicated PAPSS2 as a functional target of bupivacaine in melanoma, where its overexpression rescues drug-suppressed migration and invasion.

    Evidence Proliferation/migration/invasion assays, overexpression rescue, nude mouse tumor model

    PMID:39054720

    Open questions at the time
    • Mechanism connecting bupivacaine to PAPSS2 regulation undefined
    • Sulfation substrate in melanoma not identified
  14. 2025 Medium

    Defined the promoter-level mechanism: SOX9 derepresses Papss2 by binding and reducing the repressor C/EBPβ at a conserved Sox9-responsive element.

    Evidence Luciferase reporter, EMSA/super-shift, co-immunoprecipitation, Western blot in ATDC5 cells

    PMID:40453446

    Open questions at the time
    • Single lab
    • In vivo relevance of the C/EBPβ repression in cartilage not confirmed

Open questions

Synthesis pass · forward-looking unresolved questions
  • How tissue-specific PAPS supply is partitioned among competing sulfotransferase reactions (steroid, proteoglycan, versican) and whether PAPSS2 has regulatory roles beyond bulk PAPS provision remain open.
  • No structural model of full-length bifunctional enzyme in the corpus
  • Mechanism of sulfotransferase substrate selectivity not addressed

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0016740 transferase activity 3 GO:0140657 ATP-dependent activity 2 GO:0016787 hydrolase activity 1
Pathway
R-HSA-1266738 Developmental Biology 3 R-HSA-1430728 Metabolism 2 R-HSA-1474244 Extracellular matrix organization 2
Partners
CEBPBSOX9SULT2A1VCAN

Evidence

Reading pass · 14 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2009 PAPSS2 provides the sulfate donor PAPS required for SULT2A1-catalyzed sulfation of DHEA to DHEAS; compound heterozygous inactivating PAPSS2 mutations abolish this activity, confirmed by in vitro co-incubation of human SULT2A1 with wild-type or mutant PAPSS2 proteins, demonstrating that PAPSS2 deficiency causes androgen excess via impaired DHEA sulfation. In vitro co-incubation assay of human SULT2A1 with wild-type or mutant PAPSS2 proteins; clinical characterization of patient with compound heterozygous mutations The New England journal of medicine High 19474428
2002 PAPSS2 variant allozymes Glu10Lys and Val291Met show functionally significant reductions in PAPS synthase activity; Glu10Lys shows decreased immunoreactive protein, while Val291Met shows decreased affinity for both ATP and Na2SO4 substrates without reduction in protein level, revealing distinct catalytic mechanisms of impairment. Transient expression of variant allozymes, PAPSS activity assays, immunoreactive protein quantification, kinetic analysis (Km for ATP and Na2SO4) Pharmacogenetics High 11773860
2015 In vivo evidence that PAPSS2 mutations impair DHEA sulfation and increase 5α-reductase activity and active androgen production; a novel frameshift mutation (p.W462Cfs*3) causes complete disruption and a missense mutation (p.G270D) causes partial disruption of DHEA sulfation, confirmed by DHEA challenge test with mass spectrometry analysis of sulfation and androgen metabolites. DHEA challenge test with frequent blood sampling and urine collection, mass spectrometry metabolite analysis, in vitro functional characterization of mutations The Journal of clinical endocrinology and metabolism High 25594860
2012 PAPSS2 missense mutations identified in brachyolmia patients are loss-of-function mutations, confirmed by in vitro enzyme assays, establishing that loss of PAPSS2 enzymatic activity causes autosomal recessive brachyolmia. In vitro enzyme assays of missense mutant PAPSS2 proteins Human mutation Medium 23824674
2012 TGF-β signaling upregulates Papss2 expression in articular chondrocytes; disruption of TGF-β type II receptor (dominant-negative DNIIR mice) reduces Papss2 expression and results in decreased chondroitin-4-sulfate and increased unsulfated chondroitin sulfate in articular cartilage, with reduced biomechanical properties, placing PAPSS2 downstream of TGF-β in cartilage proteoglycan sulfation. Microarray analysis, real-time RT-PCR, Western blot, dominant-negative TGF-β receptor mouse model, Alcian blue staining, immunofluorescence for chondroitin sulfate species, mechanical indentation testing Arthritis research & therapy High 22394585
2016 SOX9 is sufficient and necessary for TGF-β-mediated regulation of PAPSS2 mRNA in chondrocytes; TGF-β post-translationally stabilizes SOX9 protein (without altering SOX9 mRNA), and SOX9 overexpression upregulates PAPSS2 mRNA, while SOX9 knockdown reduces TGF-β-mediated PAPSS2 induction. Adenovirus-mediated SOX9 overexpression, siRNA knockdown of Sox9 and Smad3, Western blot and qPCR in primary bovine articular chondrocytes and ATDC5 cells Osteoarthritis and cartilage Medium 27746378
2025 SOX9 regulates Papss2 mRNA expression by derepressing the transcriptional repressor C/EBPβ: a conserved 32bp Sox9-responsive element in the Papss2 gene was identified; C/EBPβ acts as a repressor by binding this element; SOX9 protein physically interacts with C/EBPβ (co-immunoprecipitation), prevents C/EBPβ from binding DNA, and reduces overall C/EBPβ protein levels. Luciferase reporter assays, electromobility shift assays (EMSA), super-shift assays, co-immunoprecipitation, Western blot in ATDC5 cells Gene reports Medium 40453446
2018 Snail induces PAPSS2 expression in breast cancer cells; PAPSS2 depletion reduces cell migration and lung metastasis in nude mice, while PAPSS2 overexpression promotes migration and metastasis; PAPSS2-driven sulfation of versican (VCAN) is required for Snail-mediated EMT and metastasis, as VCAN depletion dampens migration induced by Snail or PAPSS2. shRNA knockdown, overexpression, Transwell migration assays, nude mouse lung metastasis model, PAPSS inhibitor (sodium chlorate) treatment Cell death and differentiation High 29955124
2005 Loss of PAPSS2 (Papss2) activity in brachymorphic mice causes severe degenerative knee joint disease by 12 months, with cartilage damage in patello-femoral and medial compartments, demonstrating that PAPSS2 enzymatic activity is required for articular cartilage homeostasis. Histological analysis and micro-CT of Papss2 brachymorphic mutant mice (C57BL/6 background) Osteoarthritis and cartilage Medium 15882565
2012 PAPSS2 promotes osteoblast alkaline phosphatase (ALP) activity and mineralization; knockdown of PAPSS2 in MC3T3-E1 osteoblasts decreases ALP activity, mineralization, and expression of osteopontin and collagen I, and reduces phospho-Smad2/3 levels; PAPSS2 overexpression has the opposite effects, suggesting regulation through Smad signaling. Lentivirus-mediated RNAi knockdown and overexpression in MC3T3-E1 osteoblasts, ALP activity assay, mineralization assay, Western blot for phospho-Smad2/3 PloS one Medium 22916269
2022 Disease-associated mutations in the APS kinase domain of PAPSS2 cause either destabilization and aggregation of the protein or catalytic deactivation, demonstrating that the APS kinase domain is naturally fragile and that its structural integrity is required for PAPSS2 function. Cellular stability assays, aggregation measurements, characterization of clinically described disease mutations in the APS kinase domain Frontiers in molecular biosciences Medium 35463959
2000 Human PAPSS2 gene encodes a PAPS synthetase consisting of 12 exons, maps to chromosome 10q22-23, has a TATA box 21 bp upstream of the transcription initiation site, and produces a ~4.2 kb major transcript, as established by gene cloning, Northern blot, and FISH analysis. Gene cloning, Northern blot analysis, fluorescence in situ hybridization (FISH), exon-intron structure characterization Biochemical and biophysical research communications Medium 10679223
2018 PAPSS2 promotes chondrocyte differentiation in ATDC5 cells; knockdown reduces differentiation and expression of collagen II, collagen X, Wnt4, and SOX9, while overexpression promotes differentiation; data suggest PAPSS2 regulates chondrocyte differentiation via Wnt/β-catenin signaling. Lentivirus- and retrovirus-mediated PAPSS2 knockdown and overexpression in ATDC5 cells, RT-PCR, protein expression analysis Experimental and therapeutic medicine Low 30546414
2024 Bupivacaine inhibits melanoma cell proliferation and metastasis by reducing PAPSS2 expression; overexpression of PAPSS2 partially reverses bupivacaine-mediated inhibition of migration and invasion, indicating PAPSS2 is a functional target of bupivacaine in melanoma. CCK-8, EdU, clonogenic assay, Transwell migration/invasion assay, PAPSS2 overexpression rescue, in vivo nude mouse tumor model, qRT-PCR, immunohistochemistry Discovery medicine Medium 39054720

Source papers

Stage 0 corpus · 27 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2009 Inactivating PAPSS2 mutations in a patient with premature pubarche. The New England journal of medicine 117 19474428
2018 Enhanced PAPSS2/VCAN sulfation axis is essential for Snail-mediated breast cancer cell migration and metastasis. Cell death and differentiation 98 29955124
2000 Human 3'-phosphoadenosine 5'-phosphosulfate synthetase 1 (PAPSS1) and PAPSS2: gene cloning, characterization and chromosomal localization. Biochemical and biophysical research communications 63 10679223
2015 PAPSS2 deficiency causes androgen excess via impaired DHEA sulfation--in vitro and in vivo studies in a family harboring two novel PAPSS2 mutations. The Journal of clinical endocrinology and metabolism 62 25594860
2016 SOX9 protein is stabilized by TGF-β and regulates PAPSS2 mRNA expression in chondrocytes. Osteoarthritis and cartilage 46 27746378
2022 Markhor-derived Introgression of a Genomic Region Encompassing PAPSS2 Confers High-altitude Adaptability in Tibetan Goats. Molecular biology and evolution 42 36382357
2012 PAPSS2 mutations cause autosomal recessive brachyolmia. Journal of medical genetics 41 22791835
2013 Clinical and radiographic features of the autosomal recessive form of brachyolmia caused by PAPSS2 mutations. Human mutation 28 23824674
2002 Human 3'-phosphoadenosine 5'-phosphosulfate synthetase 2 (PAPSS2) pharmacogenetics: gene resequencing, genetic polymorphisms and functional characterization of variant allozymes. Pharmacogenetics 27 11773860
2012 Altered responsiveness to TGF-β results in reduced Papss2 expression and alterations in the biomechanical properties of mouse articular cartilage. Arthritis research & therapy 21 22394585
2005 Degenerative knee joint disease in mice lacking 3'-phosphoadenosine 5'-phosphosulfate synthetase 2 (Papss2) activity: a putative model of human PAPSS2 deficiency-associated arthrosis. Osteoarthritis and cartilage 20 15882565
2015 Exploring prostate cancer genome reveals simultaneous losses of PTEN, FAS and PAPSS2 in patients with PSA recurrence after radical prostatectomy. International journal of molecular sciences 15 25679447
2012 PAPSS2 promotes alkaline phosphates activity and mineralization of osteoblastic MC3T3-E1 cells by crosstalk and Smads signal pathways. PloS one 14 22916269
2022 Disease-Related Protein Variants of the Highly Conserved Enzyme PAPSS2 Show Marginal Stability and Aggregation in Cells. Frontiers in molecular biosciences 9 35463959
2005 Exclusion of the dymeclin and PAPSS2 genes in a novel form of spondyloepimetaphyseal dysplasia and mental retardation. European journal of human genetics : EJHG 7 15726110
2022 Identification of variants in ACAN and PAPSS2 leading to spondyloepi(meta)physeal dysplasias in four Chinese families. Molecular genetics & genomic medicine 6 35261200
2021 Novel Inactivating Homozygous PAPSS2 Mutation in Two Siblings With Disproportionate Short Stature. AACE clinical case reports 6 35415222
2019 Low DHEAS Concentration in a Girl Presenting with Short Stature and Premature Pubarche: A Novel PAPSS2 Gene Mutation. Hormone research in paediatrics 6 31461705
2018 The osteoarthritis-associated gene PAPSS2 promotes differentiation and matrix formation in ATDC5 chondrogenic cells. Experimental and therapeutic medicine 4 30546414
2024 Local Anesthetic Bupivacaine Inhibits Melanoma Proliferation and Metastasis by Targeting PAPSS2. Discovery medicine 3 39054720
2022 A Missense Mutation (c.1037 G > C, p. R346P) in PAPSS2 Gene Results in Autosomal Recessive form of Brachyolmia Type 1 (Hobaek Form) in A Consanguineous Family. Genes 3 36421772
2026 A novel PAPSS2 pathogenic variant: expanding the mutational spectrum and genotype-phenotype landscape in skeletal dysplasia. Journal of pediatric endocrinology & metabolism : JPEM 0 42227833
2025 Sox9 regulates Papss2 mRNA expression through derepression of the transcriptional repressor, C/EBPβ, in chondrogenic cells. Gene reports 0 40453446
2025 PAPSS2-Related Brachyolmia: Clinical and Radiographic Features and Growth Hormone Therapy of One Chinese Case. Clinical case reports 0 40927400
2024 Truncating variants in PAPSS2 gene: A cause of early prenatal onset brachyolmia? Prenatal diagnosis 0 38768012
2024 Erratum: [Corrigendum] The osteoarthritis‑associated gene PAPSS2 promotes differentiation and matrix formation in ATDC5 chondrogenic cells. Experimental and therapeutic medicine 0 39171149
2023 Bone Phenotype is Always Present But Androgen Excess is Less Frequently Seen in PAPSS2 Deficiency. Journal of clinical research in pediatric endocrinology 0 38084048

Missed literature

Know a paper Affinage missed for PAPSS2? Flag it for the maintainers and the community.

No submissions yet.